2021-02-24RELRCSBRCSBRCSB2020-10-252020-11-112020-11-112021-02-24National Institutes of Health/National Institute Of Allergy and Infectious Diseases (NIH/NIAID)AI147884United StatesNational Institutes of Health/National Institute Of Allergy and Infectious Diseases (NIH/NIAID)AI147884 01A1S1United StatesNational Institutes of Health/National Institute Of Allergy and Infectious Diseases (NIH/NIAID)AI141002United StatesNational Institutes of Health/National Institute Of Allergy and Infectious Diseases (NIH/NIAID)AI127193United StatesSARS-CoV-2 Spike Glycoprotein with three ACE2 BoundZhang JXiao TSCai YFChen BXiao TLu JZhang JJohnson RIMcKay LGAStorm NLavine CLPeng HCai YRits-Volloch SLu SQuinlan BDFarzan MSeaman MSGriffiths AChen BA trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent.Nat.Struct.Mol.Biol.US28202209202133432247doi:10.1038/s41594-020-00549-31545-9985Xiao TLu JZhang JJohnson RIMcKay LGAStorm NLavine CLPeng HCai YRits-Volloch SLu SQuinlan BDFarzan MSeaman MSGriffiths AChen BA trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent in vitro.BiorxivUS202032995768doi:10.1101/2020.09.18.301952EMD-22893associated EM volumeSARS-CoV-2 Spike Glycoprotein with three ACE2 Bound7kj4FULLOVERLAPSARS-CoV-2 Spike Glycoprotein with three ACE2 BoundSARS-CoV-2 Spike Glycoprotein with three ACE2 Bound012SARS-CoV-2 Spike Glycoprotein with three ACE2 BoundSevere acute respiratory syndrome coronavirus 2Homo sapiens610Spike glycoproteinSevere acute respiratory syndrome coronavirus 20.1365599383Homo sapiensLEVOQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFA
STEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQ
PFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLVRDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGD
SSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNIT
NLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPG
QTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQ
SYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTT
DAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA
EHVNNSYECDIPIGAGICASYQTQTNSPGGSGSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTK
TSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPS
KRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAA
LQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAI
SSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFP
QSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIV
NNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGGY
IPEAPRDGQAYVRKDGEWVLLSTFLGGSHHHHHHAngiotensin-converting enzyme 2Homo sapiens0.071024710999999993Homo sapiensLEVOLVAVTAAQSTIEEQAKTFLDKFNHEAEDLFYQSSLASWNYNTNITEENVQNMNNAGDKWSAFLKEQSTLAQMYPLQEIQN
LTVKLQLQALQQNGSSVLSEDKSKRLNTILNTMSTIYSTGKVCNPDNPQECLLLEPGLNEIMANSLDYNERLWAWESWRS
EVGKQLRPLYEEYVVLKNEMARANHYEDYGDYWRGDYEVNGVDGYDYSRGQLIEDVEHTFEEIKPLYEHLHAYVRAKLMN
AYPSYISPIGCLPAHLLGDMWGRFWTNLYSLTVPFGQKPNIDVTDAMVDQAWDAQRIFKEAEKFFVSVGLPNMTQGFWEN
SMLTDPGNVQKAVCHPTAWDLGKGDFRILMCTKVTMDDFLTAHHEMGHIQYDMAYAAQPFLLRNGANEGFHEAVGEIMSL
SAATPKHLKSIGLLSPDFQEDNETEINFLLKQALTIVGTLPFTYMLEKWRWMVFKGEIPKDQWMKKWWEMKREIVGVVEP
VPHDETYCDPASLFHVSNDYSFIRYYTRTLYQFQFQEALCQAAKHEGPLHKCDISNSTEAGQKLFNMLRLGKSEPWTLAL
ENVVGAKNMNVRPLLNYFEPLFTWLKDQNKNSFVGWSTDWSPYADSGGSHHHHHH3.4.17.232-acetamido-2-deoxy-beta-D-glucopyranose0.00022120842NAGsingleParticleparticle17.50.3NaClsodium chloride0.02Tris-HClTris hydrochlorideETHANE100277.15FEI VITROBOT MARK IVFEI TITAN KRIOSFLOOD BEAMBRIGHT FIELDFIELD EMISSION GUN300GATAN K3 BIOQUANTUM (6k x 4k)50.0514077616VYB3.4FSC 0.143 CUT-OFFRELION26298MAXIMUM LIKELIHOODMAXIMUM LIKELIHOODRELION6VYBA14-12116M17B21-610AB INITIO MODEL